Ferring Pharmaceuticals is a research-driven, biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and orthopaedics.
The company's research activities and products are connected by a common focus of providing tailored treatments that work on the body's own terms, enabling doctors to combat numerous diseases and medical conditions.
Ferring has its own production facilities in several European countries and in South America, Israel and China. It is also currently building new facilities in the US and India. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.
Ferring's marketing, medical services and sales teams, led by the corporate headquarters in Saint-Prex, Switzerland, operate from nearly 60 countries and employ 5000 people throughout the world, while treatments are available in 110 countries. This expansion has allowed Ferring to maintain a double-digit annual growth rate over the last two decades.
Areas of Expertise
Ferring focuses in the development of new medicines, however three areas of interest are key in Ferring Pharmaceuticals aspiration to improve conditions for patients all over the world. Ferring Pharmaceuticals has the world’s largest portfolio of peptide-based medicine but also excel in recombinant protein and biological therapeutics. Additionally, we are dedicated to improving methods of delivery, to make medicine as patient-friendly as possible.